ArticleTranslational cancer research2019
Noninvasive circulating tumor cell and urine cellular
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Circulating tumour cells as a window into lethality in prostate cancer.Nature reviews. Urology · 2026Review
- Diagnostic liquid biopsy biomarkers in renal cell cancer.Nature reviews. Urology · 2024Review
- The impact of XPC gene single nucleotide polymorphism rs2228001 on head and neck cancer patients' response to radiotherapy treatment.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Review
- Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).Oncology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValid cancer screening and treatment monitoring are critical for cancer patients. Although genitourinary system cancers have a high recurrence rate, when diagnosed, patients undergo surgery promptly. We sought to explore sensitive and noninvasive screening and postoperative recurrence monitoring methods, such as circulating tumor cells (CTCs) or tumor susceptibility gene detection, to determine their appropriateness for genitourinary system cancers.
methodsWe adopted multiple detection methods. Enrichment-immunofluorescence in situ hybridization (SE-iFISH) was employed to detect CTCs from the peripheral blood of patients, and Agena Bioscience MassARRAY was used to detect single-nucleotide polymorphisms (SNPs) in tumor susceptibility genes from urine cells.
resultsIn our research, CTCs showed a 76.92% positivity rate among 26 genitourinary system cancer patients, and the number of CTCs was consistent with the stage of cancer. In monitoring for bladder cancer (BC) recurrence, CTCs were more prevalent than urine cytology (66.67%
conclusionsAs a common biomarker, CTCs showed remarkable performance in cancer screening and monitoring. The noninvasive panel comprising CTCs and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.